Back to News
Market Impact: 0.15
New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
Source: WIRED
Healthcare & BiotechTechnology & Innovation
A patient-specific mRNA vaccine targeting an individual’s tumor showed results in a Phase 3 trial, described as another example of the technology’s promise in cancer treatment. The article provides no efficacy figures, trial details, or company information.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- Biotech stocks are surging. How investors can play the new drug innovation boom
- Ukraine says Starlink and Starshield high speed restrictions have been lifted
- Starlink seems to be working normally again in Ukraine
- Goldman says these top tech stocks have plenty of upside ahead of earnings
- Will AI expose the rickety infrastructure of the internet?